Ratings Bangkok Dusit Medical Services Thailand S.E.

Equities

End-of-day quote Thailand S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
27 ^THB	-0.92%		-6.09%	-2.70%

14/05	Bangkok Dusit Medical Services Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24/04	Bangkok Dusit Medical Services Public Company Limited Announces Appointment of Kongkiat Kespechara as Executive Committee Member	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
The company is in a robust financial situation considering its net cash and margin position.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

With a 2024 P/E ratio at 26.79 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company's enterprise value to sales, at 3.9 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.

	1st Jan change	Capi.	ESG Refinitiv
BANGKOK DUSIT MEDICAL SERVICES	-2.70%	1.17TCr	-
AIER EYE HOSPITAL GROUP CO., LTD.	-23.39%	1.56TCr	B+
IHH HEALTHCARE	+2.65%	1.16TCr	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+2.37%	1.01TCr	B+
ENCOMPASS HEALTH CORPORATION	+29.48%	869.89Cr	B
RAMSAY HEALTH CARE LIMITED	-10.45%	715.53Cr	A-
THE ENSIGN GROUP, INC.	+8.05%	684.58Cr	B-
MOUWASAT MEDICAL SERVICES COMPANY	-4.29%	570.56Cr	D
DALLAH HEALTHCARE COMPANY	-3.96%	429.72Cr	-
FORTIS HEALTHCARE LIMITED	+13.33%	429.78Cr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality